Your browser doesn't support javascript.
loading
Increased mast cell activation in eosinophilic chronic obstructive pulmonary disease.
Higham, Andrew; Dungwa, Josiah; Pham, Tuyet-Hang; McCrae, Christopher; Singh, Dave.
Afiliación
  • Higham A; Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health University of Manchester and Manchester University NHS Foundation Trust Manchester UK.
  • Dungwa J; Medicines Evaluation Unit The Langley Building Manchester UK.
  • Pham TH; Translational Science & Experimental Medicine Early Respiratory & Immunology, Research and Early Development, AstraZeneca, One MedImmune Way Gaithersburg MD USA.
  • McCrae C; Translational Science & Experimental Medicine Early Respiratory & Immunology, Research and Early Development, AstraZeneca, One MedImmune Way Gaithersburg MD USA.
  • Singh D; Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health University of Manchester and Manchester University NHS Foundation Trust Manchester UK.
Clin Transl Immunology ; 11(9): e1417, 2022.
Article en En | MEDLINE | ID: mdl-36188122
ABSTRACT

Objectives:

A subset of chronic obstructive pulmonary disease (COPD) patients have increased numbers of airway eosinophils associated with elevated markers of T2 inflammation. This analysis focussed on mast cell counts and mast cell-related gene expression in COPD patients with higher vs lower eosinophil counts.

Methods:

We investigated gene expression of tryptase (TPSAB1), carboxypeptidase A3 (CPA3), chymase (CMA1) and two mast cell specific gene signatures; a bronchial biopsy signature (MCbb) and an IgE signature (MCIgE) using sputum cells and bronchial epithelial brushings. Gene expression analysis was conducted by RNA-sequencing. We also examined bronchial biopsy mast cell numbers by immunohistochemistry.

Results:

There was increased expression of TPSAB1, CPA3 and MCbb in eosinophilhigh than in eosinophillow COPD patients in sputum cells and bronchial epithelial brushings (fold change differences 1.21 and 1.28, respectively, P < 0.01). Mast cell gene expression was associated with markers of T2 and eosinophilic inflammation (IL13, CLCA1, CST1, CCL26, eosinophil counts in sputum and bronchial mucosa; rho = 0.4-0.8; P < 0.05). There was no difference in MCIgE gene expression between groups. There was no difference in the total number of bronchial biopsy mast cells between groups.

Conclusion:

These results demonstrate that eosinophilic inflammation is associated with altered mast cell characteristics in COPD patients, implicating mast cells as a component of T2 inflammation present in a subset of COPD patients.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Transl Immunology Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Transl Immunology Año: 2022 Tipo del documento: Article